MedTrace Logo

Differentiation HHD From HCM (EARLY-MYO-HHD)

NCT03271385 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 465

Last updated 2022-11-17

No results posted yet for this study

Summary

Differentiating hypertrophic cardiomyopathy (HCM) from hypertensive heart disease (HHD) unavoidably encounters diagnostic challenges especially in patient of suspected HCM with history of hypertension. Diverse and overlapping forms of HCM can often lead to ambiguity when diagnosis is based on a single genetic or morphological index.

The investigators have deduced a integrated formula based on cardiac magnetic resonance (CMR) imaging and established a differentiating flow-chart between HCM and HHD, the investigators aim to identify their method in the current multi-center trial.

Conditions

Interventions

DIAGNOSTIC_TEST

evaluated by the predetermined differentiating formula

After recruiting patients, collecting the baseline data, a CMR scan will be carried out and post-processed, a predetermined differentiating formula (including left ventricular morphology, ejection fraction, presence of late gadolinium enhancement, T1 value and strain data) will be used to produce a cardiac values, which is to be input into our differentiating flow.

Sponsors & Collaborators

  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

    collaborator OTHER

  • Ruijin Hospital

    collaborator OTHER

  • LanZhou University

    collaborator OTHER

  • Kunming Medical University

    collaborator OTHER

  • Beijing Anzhen Hospital

    collaborator OTHER

  • West China Hospital

    collaborator OTHER

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Meng Jiang, MD · RenJi Hospital, School of Medicine, Shanghai Jiaotong University

  • Lianming Wu, MD · RenJi Hospital, School of Medicine, Shanghai Jiaotong University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03271385 on ClinicalTrials.gov